{"id":651626,"date":"2023-05-16T16:50:01","date_gmt":"2023-05-16T16:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=651626"},"modified":"2023-05-16T16:50:01","modified_gmt":"2023-05-16T16:50:01","slug":"aspergillosis-market-size-and-share-trends-epidemiology-and-market-forecast-2032-companies-scynexis-pulmocide-pulmatrix","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/aspergillosis-market-size-and-share-trends-epidemiology-and-market-forecast-2032-companies-scynexis-pulmocide-pulmatrix_651626.html","title":{"rendered":"Aspergillosis Market Size and Share, Trends, Epidemiology and Market Forecast 2032 | Companies – Scynexis, Pulmocide, Pulmatrix"},"content":{"rendered":"
\n
\"Aspergillosis<\/a><\/div>\n
\n
Aspergillosis Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201d Aspergillosis \u2013 Market Insights, Epidemiology, and Market Forecast-2032\u2033 report delivers an in-depth understanding of the Aspergillosis, historical and forecasted epidemiology as well as the Aspergillosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Aspergillosis – Market Insights, Epidemiology, and Market Forecast-2032<\/a>.<\/strong><\/p>\n

DelveInsight’s ” Aspergillosis – Market Insights, Epidemiology, and Market Forecast-2032<\/a>″ report delivers an in-depth understanding of the Aspergillosis, historical and forecasted epidemiology as well as the Aspergillosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/strong><\/p>\n

Some of the key facts of the Aspergillosis Market Report:<\/strong><\/p>\n

1. As per DelveInsight’s analysis, the diagnosed and treated cases of ABPA, IA and CPA were found to be 1,124,997, 37,528, and 23,831 respectively in 2019 in the 7MM.<\/p>\n

2. The market Size of Aspergillosis in the 7MM was found to be USD2,456 Million in 2019. <\/p>\n

Key benefits of the Aspergillosis  market report 2032:<\/strong><\/p>\n

1. Aspergillosis market report covers a descriptive overview and comprehensive insight of the Aspergillosis epidemiology and Aspergillosis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

2. Aspergillosis market report provides insights on the current and emerging therapies.<\/p>\n

3. Aspergillosis market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

4. Aspergillosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Aspergillosis market.<\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-market<\/a><\/strong><\/p>\n

Aspergillosis: Overview<\/strong><\/p>\n

Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs. General surgery cases only account for 2% of these, with the majority occurring in cardiac, transplant, ophthalmologic, or burn patients.<\/p>\n

The key players involved in the Aspergillosis market<\/a> are:<\/strong><\/p>\n

    \n
  1. F2G <\/li>\n
  2. Zambon SpA<\/li>\n
  3. TFF Pharmaceuticals<\/li>\n
  4. Scynexis<\/li>\n
  5. Pulmocide<\/li>\n
  6. Pulmatrix<\/li>\n<\/ol>\n

    The launch of the emerging therapies is expected to significantly impact the Aspergillosis treatment scenario in the upcoming years:-<\/strong><\/p>\n

    Drugs covered<\/strong><\/p>\n

      \n
    1. Olorofim <\/li>\n
    2. Voriconazole inhaled (ZP-059)<\/li>\n
    3. Voriconazole dry-powder inhalation (TFF-VORI).<\/li>\n
    4. Ibrexafunger<\/li>\n
    5. PC945<\/li>\n
    6. Pulmazole (PUR1900)<\/li>\n<\/ol>\n

      Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/aspergillosis-market<\/a><\/strong><\/p>\n

      Table of Contents<\/strong><\/p>\n

      1. Report Introduction<\/p>\n

      2. Executive Summary<\/p>\n

      3. SWOT analysis<\/p>\n

      4. Aspergillosis Patient Share (%) Overview at a Glance<\/p>\n

      5. Aspergillosis Market Overview at a Glance<\/p>\n

      6. Aspergillosis Disease Background and Overview<\/p>\n

      7. Aspergillosis Epidemiology and Patient Population<\/p>\n

      8. Country-Specific Patient Population of Aspergillosis<\/p>\n

      9. Aspergillosis Current Treatment and Medical Practices<\/p>\n

      10. Unmet Needs<\/p>\n

      11. Aspergillosis Emerging Therapies<\/p>\n

      12. Aspergillosis Market Outlook<\/p>\n

      13. Country-Wise Aspergillosis Market Analysis (2019–2032)<\/p>\n

      14. Market Access and Reimbursement of Therapies<\/p>\n

      15. Market drivers<\/p>\n

      16. Market barriers<\/p>\n

      17. Appendix<\/p>\n

      18. Aspergillosis Report Methodology<\/p>\n

      19. DelveInsight Capabilities<\/p>\n

      20. Disclaimer<\/p>\n

      21. About DelveInsight<\/p>\n

      Related Reports:<\/strong><\/p>\n

      Aspergillosis – Pipeline Insights, 2023<\/strong><\/p>\n

      “Aspergillosis Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Aspergillosis market. A detailed picture of the Aspergillosis pipeline landscape is provided, which includes the disease overview and Aspergillosis treatment guidelines.<\/p>\n

      Aspergillosis – Epidemiology Forecast to 2032<\/strong><\/p>\n

      DelveInsight’s ‘Aspergillosis – Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Aspergillosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

      Aspergillosis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020<\/strong><\/p>\n

      “Aspergillosis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020” report by DelveInsight offers comprehensive insights on marketed and Phase III products for Actinic Keratosis.The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023.<\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      Aspergillosis Market DelveInsight\u2019s \u201d Aspergillosis \u2013 Market Insights, Epidemiology, and Market Forecast-2032\u2033 report delivers an in-depth understanding of the Aspergillosis, historical and forecasted epidemiology as well as the Aspergillosis market trends in the United States, EU5 (Germany, Spain, Italy, France, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-651626","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/651626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=651626"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/651626\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=651626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=651626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=651626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}